Skip to main content
World Journal of Gastroenterology logoLink to World Journal of Gastroenterology
. 2003 Apr 15;9(4):660–664. doi: 10.3748/wjg.v9.i4.660

Tributyrin inhibits human gastric cancer SGC-7901 cell growth by inducing apoptosis and DNA synthesis arrest

Jun Yan 1, Yong-Hua Xu 1
PMCID: PMC4611423  PMID: 12679905

Abstract

AIM: To evaluate the effects of tributyrin, a pro-drug of natural butyrate and a neutral short-chain fatty acid triglyceride, on the growth inhibition of human gastric cancer SGC-7901 cell.

METHODS: Human gastric cancer SGC-7901 cells were exposed to tributyrin at 0.5, 1, 2, 5, 10 and 50 mmol·L-1 for 24-72 h. MTT assay was applied to detect the cell proliferation. [3H]-TdR uptake was measured to determine DNA synthesis. Apoptotic morphology was observed by electron microscopy and Hoechst-33258 staining. Flow cytometry and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay were performed to detect tributyrin-triggered apoptosis. The expressions of PARP, Bcl-2 and Bax were examined by Western blot assay.

RESULTS: Tributyrin could initiate growth inhibition of SGC-7901 cell in a dose- and time-dependent manner. [3H]-TdR uptake by SGC-7901 cells was reduced to 33.6% after 48 h treatment with 2 mmol·L-1 tributyrin, compared with the control (P < 0.05). Apoptotic morphology was detected by TUNEL assay. Flow cytometry revealed that tributyrin could induce apoptosis of SGC-7901 cells in dose-dependent manner. After 48 hours incubation with tributyrin at 2 mmol·L-1, the level of Bcl-2 protein was lowered, and the level of Bax protein was increased in SGC-7901, accompanied by PARP cleavage.

CONCLUSION: Tributyrin could inhibit the growth of gastric cancer cells effectively in vitro by inhibiting DNA synthesis and inducing apoptosis, which was associated with the down-regulated Bcl-2 expression and the up-regulated Bax expression. Therefore, tributyrin might be a promising chemopreventive and chemotherapeutic agent against human gastric carcinogenesis.

INTRODUCTION

Gastric cancer is one of the most common causes of malignancy-related death worldwide. In China, the annual average mortality rate of gastric carcinoma is as high as 16 per 100 thousand[1]. Environmental factors, diet that is high in salts and low in fresh fruit and vegetables are regarded as the risk of stomach cancer[2-6]. Although plenty of advances have been made in the gastrointestinal medicine, the inability to diagnose early and treat effectively of the gastric cancer remains an unsolved problem for clinicians[7-23].

Chemoprevention and chemotherapy including the use of natural products, synthetic compounds or dietary substances are promising ways to stop or reverse the process of carcinogenesis[24]. Large number of minor dietary components has been found to inhibit carcinogenesis at various stages[25]. Tributyrin is a neutral short-chain fatty acid triglyceride existed in some spice plants at low levels in nature[26], and has been approved as a food additive in the United States[27]. Tributyrin is also a pro-drug of natural butyrate synthesized by the bacterial fermentation of various complex carbohydrates unabsorbed in the digestive tract[28] and has been reported bearing anti-tumor effect on neoplastic cells[27,29,30] as well as inhibiting proliferation and stimulating differentiation in multiple cancer cell lines. Most importantly, tributyrin is more lipophilic compared with the butyrate and can be metabolized by the intracellular lipases, progressively releasing therapeutically effective butyrate directly in the cell[26,31]. However, the underlying mechanisms of tributyrin against different types of tumor remain to be understood and so far, the effect of tributyrin on gastric cancer cells has not been reported yet.

In this study, we are trying to evaluate the ability of tributyrin to inhibit cell proliferation, arrest DNA synthesis and induce apoptosis in human gastric cancer SGC-7901 cells and go further into some apoptosis-related events in these processes.

MATERIALS AND METHODS

Cell lines and reagents

Human gastric cancer cell line SGC-7901 was provided by the Cell Bank of Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). Cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM; Life Technologies Inc., Grand Island, NY) supplemented with 10% fetal calf serum (FCS; Life Technologies Inc., Rockville, MD), penicillin (100 kU·L-1) and streptomycin (0.1 g·L-1) at 37 °C in a 5% CO2-95% air atmosphere. Antibodies against Bax, Bcl-2, PARP, and Actin were obtained from Santa Cruz. Other chemicals used in the study were purchased from Sigma Chemical Co (St. Louis, MO, USA). In situ cell death detection kit was purchased from Roche Diagnostics. [3H]-TdR was obtained from Amersham Company.

Assessment of cell proliferation

MTT assay was conducted to determine the cell proliferation. SGC-7901 cells were seeded in a 96-well plate (1 × 104·well-1) as described previously[32]. In brief, after 24 h incubation cells were treated with tributyrin for three days and untreated cells served as a control. Prior to the determination, 5 µL of the 2.5 g·L-1 stock solution of 3-[4,5-dimethylthiaolyl]-2,5-diphenyl-tetrazolium bromide (MTT) was added to each well. After 4 h incubation, the culture media were discarded followed by addition of 100 µL of DMSO to each well and vibration for 10 min. The absorbance (A) was measured at 492 nm with a microplate reader. The percentage of viable cells was calculated as follows: (A of experimental group/A of control group) × 100%.

[3H]-TdR incorporation

The cells were treated with 2 mmol·L-1 Tributyrin for the indicated time as described previously[33]. 74 kBq of [3H]-TdR were added to cells 3 h before the end of the culture. Cells were then washed with ice-cold PBS and 5% trichloroacetic acid and lyzed in 0.25 mol·L-1 NaOH. The lysates were neutralized with 3 mol·L-1 HCl and [3H]-TdR uptake was measured with Beckman LS5000 TD liquid scintillation counter.

Transmission electron microscopy

The cultured cells treated with 2 mmol·L-1 tributyrin for 48 h were trypsinized and harvested, respectively. Subsequently the cells were immersed with Epon 821, embedded in capsules and converged at 60 °C for 72 h, then they were prepared into ultrathin section (60 nm) and stained with uranyl acetate and lead citrate. Cell ultrastructure was examined by transmission electron microscopy.

Morphological change of apoptosis

The morphological changes of cell apoptosis were determined under fluorescence microscope. Briefly, the experimental cells were pelleted and fixed in 200 ml·L-1 ethanol/phosphate-buffered saline (PBS), stained with 5 mg·L-1 Hoechst-33258 for 10 min at room temperature, then visualized under fluorescence microscope.

TUNEL assay

Apoptosis of SGC-7901 cells was analyzed by using in situ cell death detection kit. The method is essentially based on the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique. In brief, after cells were treated with or without tributyrin for the indicated time, they were fixed overnight in 100 g·L-1 formaldehyde, then treated with proteinase K and H2O2, labeled with fluorescein dUTP in a humid box at 37 °C for 1 h and visualized under fluorescence microscope. The cells without addition of TdT enzyme were used as negative control.

Flow cytometry

After harvested, the experimental cells were washed with PBS twice and fixed with 700 mL·L-1 ethanol at 4 °C overnight. The fixed cells were washed twice with PBS and stained with 800 µL propidium iodide and 200 µL deoxyribonulcease-free ribonuclease A in PBS. The fluorescence density of propidium iodide-stained nuclei was determined by flow cytometry.

Western blot analysis

The experimental cells were lysed in lysis buffer [25 mmol·L-1 HEPES, 1.5% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 0.5 mol·L-1 NaCl, 5 mmol·L-1 EDTA, 50 mmol·L-1 NaF, 0.1 mmol·L-1 sodium vanadate, 1 mmol·L-1 phenylmethylsulfonyl fluoride (PMSF), and 0.1 g·L-1 leupeptin (pH7.8)] at 4 °C with sonication. The lysates were centrifuged at 15000 g for 15 min at 4 °C and the proteins were separated on SDS-PAGE, transferred to nitrocellulose filter and incubated with antibodies against Bcl-2, Bax, PARP, and Actin, respectively. Then the membrane was incubated with peroxidase-conjugated secondary antibodies. Detection was performed with enhanced chemiluminescence reagent.

Statistical analysis

Student’s t test was used to assess statistical significance of differences. If P < 0.05, the difference was considered statistically significant.

RESULTS

Inhibition of human gastric cancer SGC-7901 cell proliferation by tributyrin

The experimental SGC-7901 cells were treated with various concentrations of tributyrin for 1-3 d and the cell viability was determined as described above by MTT assay. As shown in Figure 1, tributyrin could inhibit the growth of gastric cancer cells in a dose- and time-dependent manner. Cell growth was suppressed by 24.9%, 36.6%, 50.3%, 60.6%, 84.1% and 91.3% after 72 h treatment with tributyrin at 0.5, 1, 2, 5, 10 and 50 mmol·L-1, respectively. It was noted that tributyrin at 50 mmol·L-1 had an inhibitory effect of more than 90% on the tumor cell growth after 48-72 h treatment. The IC50 value of tributyrin for SGC-7901 cell at 72 h was 2 mmol·L-1.

Figure 1.

Figure 1

Effect of tributyrin on cell growth in SGC-7901 cells. The cells were treated with various concentrations of tribu-tyrin for 24, 48 and 72 h. The antiproliferative effect was mea-sured by MTT assay. Results were expressed as the means ± SD from three independent determinations.

DNA synthesis arrest by tributyrin

Since the IC50 value of tributyrin was 2 mmol·L-1, the concentration was used for the following assay. Tributyrin inhibited the [3H]-TdR uptake by SGC-7901 cells in a time-dependent manner. Compared with the control, the DNA synthesis of tumor cells was significantly reduced by 66.4%, 92.2% and 90.1% after 48 h, 72 h and 96 h treatment with tributyrin, respectively, (P < 0.05, Figure 2).

Figure 2.

Figure 2

Inhibitory effect of tributyrin on DNA synthesis in-corporated with 3H-TdR. With the concentration of 2 mmol·L-1, tributyrin inhibited the [3H]-TdR uptake by SGC-7901 cells in a time-dependent manner. Results were expressed as means ± SD from three independent determinations.

Tributyrin induction of apoptosis

Morphological changes After 48 h of exposure to tributyrin, gastric cancer cells began to show morphologic features of apoptosis, which manifested as cell shrinkage, chromatin condensation and nuclear pyknosis, etc by transmission electron microscopy (Figure 3). The tributyrin-treated SGC-7901 cells labeled with Hoechst-33258 also showed apoptotic features including nuclear shrinkage or fragmentation by fluorescence microscopy (Figure 4).

Figure 3.

Figure 3

Ultrastructural changes of the gastric cancer cells treated with 2 mmol·L-1 tributyrin for 48 h. (A) The control SGC-7901 cell; (B) the experimental cell showing early changes of apoptosis in which nuclear chromatin condensation and cell shrinkage were observed (B).

Figure 4.

Figure 4

Tributyrin-induced apoptosis in SGC-7901 cells stained with Hoechst-33258. A: the control SGC-7901 cells; B: the experimental cells showing nuclear shrinkage or fragmentation.

TUNEL assay

The TUNEL assay revealed that tributyrin could induce the apoptosis of SGC-7901 cells, while the negative control did not show any signs of fluorescence signals (Figure 5).

Figure 5.

Figure 5

Tributyrin-induced apoptosis by TUNEL assay. A: the positive control cells; B: the negative control cells; C: the experi-mental cells treated with tributyrin at 2 mmol·L-1 for 2 d.

Flow cytometry

Cell cycle analysis in SGC-7901 cells treated with tributyrin revealed that a sub-G1 apoptotic peak appeared (Figure 6). The apoptosis rate in tributyrin-treated tumor cells was increased in a time- and dose-dependent manner. When treated with 2 mmol·L-1 tributyrin for 72 h, the experimental SGC-7901 cells showed a 41.5% of apoptosis.

Figure 6.

Figure 6

Tributyrin-induced apoptosis in SGC-7901 cells by flow cytometry. (A) The control cells, (B)-(D) The experimental cells treated with tributyrin at 0.5, 2 and 10 mmol·L-1 respectively for 48 h. (E) Apoptosis rates in SGC-7901 cells treated with 0.5, 2 and 10 mmol·L-1 or without tributyrin for the indicated times.

Differential expression of Bcl-2 and Bax protein and PARP cleavage in tributyrin-treated cells

After treated with indicated concentrations of tributyrin for 48 h, the expression of Bcl-2 protein was markedly decreased while that of Bax displayed an increased trend. PARP cleavage in the experimental cells appeared at 0.5 mmol·L-1 and was obvious at 2 mmol·L-1 of tributyrin treatment for 48 h (Figure 7).

Figure 7.

Figure 7

The expression of Bcl-2, Bax protein and PARP cleav-age in tributyrin-treated SGC-7901 cells. (1) The control cells; (2)-(4) The experimental cells treated with tributyrin for 48 h at 0.5, 2 and 10 mmol.L-1, respectively.

DISCUSSION

It has been reported tributyrin, a substance that naturally exists in some foods, was a potent agent against various malignancies, including colon and pancreas carcinomas, and that 1 mmol of tributyrin could result in an inhibitory effect comparable with 3 mmol of butyrate[32,33]. The high lipophilic property and the long duration in blood made tributyrin a promising anti-tumor agent. However, the effects of tributyrin on gastric cancer cells have not been reported.

The present study demonstrated that tributyrin could inhibit the growth of human gastric cancer SGC-7901 cells in a dose-and time-dependent manner, which might be caused by DNA synthesis arrest as shown in our experiment via preventing SGC-7901 cells from progressing into S-phase and ultimately blocking the cell proliferation. The inhibition of DNA synthesis was more than 90% when SGC-7901 cells were treated with tributyrin at 2 mmol·L-1 for 48-72 h.

Besides DNA synthesis arrest, the induced cell death was another major reason for the cell growth inhibition. Apoptosis, also called programmed cell death, is a natural process of cell suicide which plays a critical role in the development and homeostasis of metazoans[34,35]. Our results that tributyrin could induce apoptosis in SGC-7901 cells revealed by the typical apoptotic alterations, including the morphological changes by electron microscopy, positive Hoechst-33258 staining, DNA fragmentation by TUNEL assay and apoptotic sub-G1 peak by flow cytometry.

Apoptosis is a complex process regulated by a variety of factors[36-39]. The members of the Bcl-2 family are important regulators in the apoptotic pathway with individual members that can suppress (eg Bcl-2, Bcl-xl) or promote (eg Bax, Bad) apoptosis. As an oncogene-derived protein, Bcl-2 confers a negative control in the pathway of cellular suicide machinery, whereas Bax, a Bcl-2-homologous protein, promotes cell death by competing with Bcl-2. Introduction of Bcl-2 into most eukaryotic cells has been reported to be able to protect the recipient cell from a wide variety of stress applications that lead to cell death[40,41]. In the present study, we observed that the expression of Bcl-2 was reduced and that of Bax was up-regulated, indicating the reduced ratio of Bcl-2/Bax might serve as a mechanism of SGC-7901 cells apoptosis induced by tributyrin. Its subsequent event might be the release of cytochrome c and caspase-3 activation. On the other hand, the cleavage of PARP, one of caspase-3 downstream target[42], was also observed in the experimental SGC-7901 cells with the increase of tributyrin concentrations. However, PARP could also be cleaved through a parallel caspase-3 independent pathway. Therefore, the exact mechanism underlying the apoptosis of SGC-7901 cells needed to be further investigated.

In summary, we have demonstrated that tributyrin, an oral analogue of butyrate, could induce DNA synthesis arrest and apoptosis in human gastric cancer SGC-7901 cells in vitro. The effect was dose- and time-dependent. The apoptotic mechanism of the SGC-7901 cells induced by tributyrin was at least via the reduction of Bcl-2/Bax ratio. These data suggested that further evaluation of tributyrin, a promising anti-tumor agent, for the treatment gastric cancer was warranted.

ACKNOWLEDGEMENTS

We thank Dr. Rugang Zhang from Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, for his helpful suggestion.

Footnotes

Supported by the Major State Basic Research (973) Program of China, (G1999053905) and National Natural Science Foundation of China, No. 30170207

Edited by Zhu L

References

  • 1.Xue FB, Xu YY, Wan Y, Pan BR, Ren J, Fan DM. Association of H. pylori infection with gastric carcinoma: a Meta analysis. World J Gastroenterol. 2001;7:801–804. doi: 10.3748/wjg.v7.i6.801. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Sugie S, Okamoto K, Watanabe T, Tanaka T, Mori H. Suppressive effect of irsogladine maleate on N-methyl-N-nitro-N-nitrosoguanidine (MNNG)-initiated and glyoxal-promoted gastric carcinogenesis in rats. Toxicology. 2001;166:53–61. doi: 10.1016/s0300-483x(01)00447-4. [DOI] [PubMed] [Google Scholar]
  • 3.Palli D, Russo A, Saieva C, Salvini S, Amorosi A, Decarli A. Dietary and familial determinants of 10-year survival among patients with gastric carcinoma. Cancer. 2000;89:1205–1213. doi: 10.1002/1097-0142(20000915)89:6<1205::aid-cncr3>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  • 4.Mathew A, Gangadharan P, Varghese C, Nair MK. Diet and stomach cancer: a case-control study in South India. Eur J Cancer Prev. 2000;9:89–97. doi: 10.1097/00008469-200004000-00004. [DOI] [PubMed] [Google Scholar]
  • 5.Palli D. Epidemiology of gastric cancer: an evaluation of available evidence. J Gastroenterol. 2000;35 Suppl 12:84–89. [PubMed] [Google Scholar]
  • 6.Palli D, Russo A, Ottini L, Masala G, Saieva C, Amorosi A, Cama A, D'Amico C, Falchetti M, Palmirotta R, et al. Red meat, family history, and increased risk of gastric cancer with microsatellite instability. Cancer Res. 2001;61:5415–5419. [PubMed] [Google Scholar]
  • 7.Skoropad V, Berdov B, Zagrebin V. Concentrated preoperative radiotherapy for resectable gastric cancer: 20-years follow-up of a randomized trial. J Surg Oncol. 2002;80:72–78. doi: 10.1002/jso.10102. [DOI] [PubMed] [Google Scholar]
  • 8.Yao XX, Yin L, Sun ZC. The expression of hTERT mRNA and cellular immunity in gastric cancer and precancerosis. World J Gastroenterol. 2002;8:586–590. doi: 10.3748/wjg.v8.i4.586. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Fahey JW, Haristoy X, Dolan PM, Kensler TW, Scholtus I, Stephenson KK, Talalay P, Lozniewski A. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci USA. 2002;99:7610–7615. doi: 10.1073/pnas.112203099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Martin RC, Jaques DP, Brennan MF, Karpeh M. Extended local resection for advanced gastric cancer: increased survival versus increased morbidity. Ann Surg. 2002;236:159–165. doi: 10.1097/00000658-200208000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Yu WL, Huang ZH. Progress in studies on gene therapy for gas-tric cancer. Shijie Huaren Xiaohua Zazhi. 1999;7:887–889. [Google Scholar]
  • 12.Chen GY, Wang DR. The expression and clinical significance of CD44v in human gastric cancers. World J Gastroenterol. 2000;6:125–127. doi: 10.3748/wjg.v6.i1.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wang RQ, Fang DC, Liu WW. MUC2 gene expression in gastric cancer and preneoplastic lesion tissues. Shijie Huaren Xiaohua Zazhi. 2000;8:285–288. [Google Scholar]
  • 14.Guo YQ, Zhu ZH, Li JF. Flow cytometric analysis of apoptosis and proliferation in gastric cancer and precancerous lesion. Shijie Huaren Xiaohua Zazhi. 2000;8:983–987. [Google Scholar]
  • 15.Chen SY, Wang JY, Ji Y, Zhang XD, Zhu CW. Effects of Helicobacter pylori and protein kinase C on gene mutation in gastric cancer and precancerous lesions. Shijie Huaren Xiaohua Zazhi. 2001;9:302–307. [Google Scholar]
  • 16.Xu AG, Li SG, Liu JH, Gan AH. Function of apoptosis and expression of the proteins Bcl-2, p53 and C-myc in the development of gastric cancer. World J Gastroenterol. 2001;7:403–406. doi: 10.3748/wjg.v7.i3.403. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Zhou HP, Wang X, Zhang NZ. Early apoptosis in intestinal and diffuse gastric carcinomas. World J Gastroenterol. 2000;6:898–901. doi: 10.3748/wjg.v6.i6.898. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Zhang FX, Zhang XY, Fan DM, Deng ZY, Yan Y, Wu HP, Fan JJ. Antisense telomerase RNA induced human gastric cancer cell apoptosis. World J Gastroenterol. 2000;6:430–432. doi: 10.3748/wjg.v6.i3.430. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Gu QL, Li NL, Zhu ZG, Yin HR, Lin YZ. A study on arsenic trioxide inducing in vitro apoptosis of gastric cancer cell lines. World J Gastroenterol. 2000;6:435–437. doi: 10.3748/wjg.v6.i3.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Wu K, Shan YJ, Zhao Y, Yu JW, Liu BH. Inhibitory effects of RRR-alpha-tocopheryl succinate on benzo(a)pyrene (B(a)P)-induced forestomach carcinogenesis in female mice. World J Gastroenterol. 2001;7:60–65. doi: 10.3748/wjg.v7.i1.60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Jung YD, Mansfield PF, Akagi M, Takeda A, Liu W, Bucana CD, Hicklin DJ, Ellis LM. Effects of combination anti-vascular endot-helial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer. 2002;38:1133–1140. doi: 10.1016/s0959-8049(02)00013-8. [DOI] [PubMed] [Google Scholar]
  • 22.Cui RT, Cai G, Yin ZB, Cheng Y, Yang QH, Tian T. Transretinoic acid inhibits rats gastric epithelial dysplasia induced by N-methyl-N-nitro-N-nitrosoguanidine: influences on cell apoptosis and expression of its regulatory genes. World J Gastroenterol. 2001;7:394–398. doi: 10.3748/wjg.v7.i3.394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.González CA, Sala N, Capellá G. Genetic susceptibility and gastric cancer risk. Int J Cancer. 2002;100:249–260. doi: 10.1002/ijc.10466. [DOI] [PubMed] [Google Scholar]
  • 24.Morse MA, Stoner GD. Cancer chemoprevention: principles and prospects. Carcinogenesis. 1993;14:1737–1746. doi: 10.1093/carcin/14.9.1737. [DOI] [PubMed] [Google Scholar]
  • 25.Wattenberg LW. Inhibition of carcinogenesis by minor dietary constituents. Cancer Res. 1992;52(Suppl 7):S2024–S2029. [PubMed] [Google Scholar]
  • 26.Bach A, Métais P. [Fats with short and medium chains. Physiological, biochemical, nutritional, and therapeutic aspects] Ann Nutr Aliment. 1970;24:75–144. [PubMed] [Google Scholar]
  • 27.Heerdt BG, Houston MA, Anthony GM, Augenlicht LH. Initiation of growth arrest and apoptosis of MCF-7 mammary carcinoma cells by tributyrin, a triglyceride analogue of the short-chain fatty acid butyrate, is associated with mitochondrial activity. Cancer Res. 1999;59:1584–1591. [PubMed] [Google Scholar]
  • 28.Scheppach W. Effects of short chain fatty acids on gut morphology and function. Gut. 1994;35:S35–S38. doi: 10.1136/gut.35.1_suppl.s35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Schröder C, Eckert K, Maurer HR. Tributyrin induces growth inhibitory and differentiating effects on HT-29 colon cancer cells in vitro. Int J Oncol. 1998;13:1335–1340. doi: 10.3892/ijo.13.6.1335. [DOI] [PubMed] [Google Scholar]
  • 30.Maier S, Reich E, Martin R, Bachem M, Altug V, Hautmann RE, Gschwend JE. Tributyrin induces differentiation, growth arrest and apoptosis in androgen-sensitive and androgen-resistant human prostate cancer cell lines. Int J Cancer. 2000;88:245–251. [PubMed] [Google Scholar]
  • 31.Egorin MJ, Yuan ZM, Sentz DL, Plaisance K, Eiseman JL. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother Pharmacol. 1999;43:445–453. doi: 10.1007/s002800050922. [DOI] [PubMed] [Google Scholar]
  • 32.Ying H, Yu Y, Xu Y. Cloning and characterization of F-LANa, upregulated in human liver cancer. Biochem Biophys Res Commun. 2001;286:394–400. doi: 10.1006/bbrc.2001.5390. [DOI] [PubMed] [Google Scholar]
  • 33.Clarke KO, Feinman R, Harrison LE. Tributyrin, an oral butyrate analogue, induces apoptosis through the activation of caspase-3. Cancer Lett. 2001;171:57–65. doi: 10.1016/s0304-3835(01)00574-2. [DOI] [PubMed] [Google Scholar]
  • 34.Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309–1312. doi: 10.1126/science.281.5381.1309. [DOI] [PubMed] [Google Scholar]
  • 35.Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999;11:255–260. doi: 10.1016/s0955-0674(99)80034-9. [DOI] [PubMed] [Google Scholar]
  • 36.Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322–1326. doi: 10.1126/science.281.5381.1322. [DOI] [PubMed] [Google Scholar]
  • 37.Li HL, Chen DD, Li XH, Zhang HW, Lü JH, Ren XD, Wang CC. JTE-522-induced apoptosis in human gastric adenocarcinoma [correction of adenocarcinoma] cell line AGS cells by caspase activation accompanying cytochrome C release, membrane translocation of Bax and loss of mitochondrial membrane potential. World J Gastroenterol. 2002;8:217–223. doi: 10.3748/wjg.v8.i2.217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Fan XQ, Guo YJ. Apoptosis in oncology. Cell Res. 2001;11:1–7. doi: 10.1038/sj.cr.7290060. [DOI] [PubMed] [Google Scholar]
  • 39.Yuan RW, Ding Q, Jiang HY, Qin XF, Zou SQ, Xia SS. Bcl-2, P53 protein expression and apoptosis in pancreatic cancer. Shijie Huaren Xiaohua Zazhi. 1999;7:851–854. [Google Scholar]
  • 40.Basu A, Haldar S. The relationship between BcI2, Bax and p53: consequences for cell cycle progression and cell death. Mol Hum Reprod. 1998;4:1099–1109. doi: 10.1093/molehr/4.12.1099. [DOI] [PubMed] [Google Scholar]
  • 41.Chang YC, Xu YH. Expression of Bcl-2 inhibited Fas-mediated apoptosis in human hepatocellular carcinoma BEL-7404 cells. Cell Res. 2000;10:233–242. doi: 10.1038/sj.cr.7290052. [DOI] [PubMed] [Google Scholar]
  • 42.Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM. Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell. 1995;81:801–809. doi: 10.1016/0092-8674(95)90541-3. [DOI] [PubMed] [Google Scholar]

Articles from World Journal of Gastroenterology : WJG are provided here courtesy of Baishideng Publishing Group Inc

RESOURCES